Following U.S. Stocks were among the “Top Losers” during Monday’s trade: Juno Therapeutics Inc (NASDAQ:JUNO), Diamond Offshore Drilling Inc (NYSE:DO) , EXACT Sciences Corporation (NASDAQ:EXAS), Arrowhead Research Corp (NASDAQ:ARWR)

Their insights are depicted underneath:

Juno Therapeutics Inc (NASDAQ:JUNO)’s shares dwindled -4.73%, and closed at $50.34.

Through GLOBE NEWSWIRE, Juno Therapeutics Inc. (JUNO), declared that it will webcast its presentations at the below listed investor conferences in March.

Steve Harr, chief financial officer of Juno, will present at the 2015 Barclays Global Healthcare Conference at 10:45 a.m. EDT, Wednesday, March 11, 2015 at the Loews Miami Beach Hotel in Miami

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical corporation focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies in addition to solid tumors.

Diamond Offshore Drilling Inc (NYSE:DO), declined -4.61%, and closed at $28.15, hitting new 52-week low of $27.62. The stock has the beta value of 1.28, and its volatility for the week is 4.01%, while for the month it is 5.09%. The company has the market capitalization of $4.05B. The mean recommendation of analysts for this stock is 3.80.(where 1=Buy, 5=Sale).

Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. The corporation provides services in floater market, such as ultra-deepwater, deepwater, and mid-water; and non-floater or jack-up market.

EXACT Sciences Corporation (NASDAQ:EXAS), dipped -4.57%, and closed at $23.83.

Through BUSINESS WIRE, Exact Sciences Corporation (EXAS) and Ironwood Pharmaceuticals, Inc. (IRWD) declared recently an contract to co-promote Exact Sciences’ Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. The contract provides for the near-term expansion of Cologuard promotional efforts through the use of Ironwood’s clinical sales specialists to more than double the number of physicians reached in the United States. The non-exclusive co-promotion contract covers an initial one-year term with the opportunity for extension.

Ironwood’s clinical sales specialists are predictable to start Cologuard promotional efforts in the second quarter of 2015, educating health care practitioners to whom they presently detail LINZESS® (linaclotide). LINZESS is the first and only approved therapy in a class of drugs that works differently to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) in adults. The contract augments Exact Sciences’ 140 sales representatives with Ironwood’s team of about 160 sales representatives.

Under the terms of the deal, Ironwood will be compensated from the net sales generated from the physicians on whom they call. LINZESS will remain the first-position product for the Ironwood sales team. Exact Sciences will maintain responsibility for all other aspects of commercialization of Cologuard. The companies will also collaborate on medical education initiatives to support more in-depth understanding of Cologuard and the importance of colorectal cancer screening.

Cologuard is the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer. Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy-to-use screening test. Cologuard is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. Cologuard found 92 percent of colorectal cancers with 87 percent specificity in a cross-sectional study that comprised of 10,000 average risk patients.

Arrowhead Research Corp (NASDAQ:ARWR), dropped -4.52%, and closed at $7.40.

Through BUSINESS WIRE, Arrowhead Research Corp. (ARWR), a biopharmaceutical corporation developing targeted RNAi therapeutics, declared the attainment of Novartis’ entire RNAi research and development portfolio and associated assets. The attainment comprises assignment of certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, an exclusive license in the RNAi field to other patents and patent applications owned or controlled by Novartis, assignment of a third party license, three pre-clinical RNAi candidates, and other related assets.

Key aspects of the attainment comprise the following:

• Multiple patent families covering RNAi-trigger design rules and modifications that fall outside of key patents controlled by competitors, which the Corporation believes provides freedom to operate for any target and indication;
• Novel intracellular targeting ligands that enhance the activity of RNAi-triggers by targeting the RNA-induced silencing complex (RISC) more effectively and improving stability once RISC is loaded;
• An assignment of Novartis’ license from Alnylam Pharmaceuticals granting Arrowhead access to Alnylam intellectual property, not including delivery, for 30 gene targets chosen by Novartis;
• A pipeline of three candidates initiated by Novartis and for which Novartis has developed varying amounts of preclinical data.

Arrowhead Research Corporation is a biopharmaceutical corporation developing targeted RNAi therapeutics. The corporation is leveraging its proprietary Dynamic Polyconjugate™ delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes.